Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 27Parkinson Disease 4, Autosomal Dominant Lewy Body 24Neoplasms 14Melanoma 9Endometrial Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Cholangiocarcinoma 6Stomach Neoplasms 4Recurrence 4Carcinoma 4Biliary Tract Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Paraganglioma, Extra-Adrenal 2Osteosarcoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Glioma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, Hurthle cell 1

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × lenvatinib × Clear all
NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡